Heitz Florian, Kümmel Sherko, Lederer Bianca, Solbach Christine, Engels Knut, Ataseven Beyhan, Sinn Bruno, Blohmer Jens Uwe, Denkert Carsten, Barinoff Jana, Fisseler-Eckhoff Annette, Loibl Sibylle
Department of Gynaecology and Gynaecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Germany.
Department of Gynaecology and Gynaecologic Oncology, Charité University, Berlin, Germany.
Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1110-1117. doi: 10.1055/a-0987-9898. Epub 2019 Oct 22.
Oestrogen receptor beta (ER-β) is abundantly expressed in breast cancer (BC), but its impact on neoadjuvant chemotherapy outcome is unknown. Patients treated in the neoadjuvant GeparTrio trial with available tissue for immunohistochemical analyses were included. Nuclear ER-β expression was correlated with clinico-pathologic characteristics. The impact of its expression on pathological complete response (pCR [ypT0/ypN0]) and survival was determined. Samples of 570 patients were available. Low nuclear ER-β expression (IRS < 9) was observed in 48.4% of hormone receptor positive and 58.6% of hormone receptor negative tumours. Low nuclear ER-β expression was associated with higher pCR rates compared to high nuclear ER-β expression (16.1% vs. 4.7%, p = 0.026). Low ER-β expression was no independent predictor of pCR in multivariate analyses. Disease-free and overall survival were not statistically different between patients with high and low nuclear ER-β expression. Triple-negative BCs showed low nuclear ER-β expression in 57.7%, and pCR rates were 27.1% and 0% (p = 0.23) in low and high ER-β expressing tumours, respectively. Low ER-β expression is associated with improved pCR rates in univariate analyses. However multivariate analyses and survival analyses do not indicate an impact of ER-β on survival in patients undergoing neoadjuvant chemotherapy. Further examination of ER-β as predictor for endocrine therapy might be of value.
雌激素受体β（ER-β）在乳腺癌（BC）中大量表达，但其对新辅助化疗结果的影响尚不清楚。纳入在新辅助GeparTrio试验中接受治疗且有可用组织进行免疫组织化学分析的患者。核ER-β表达与临床病理特征相关。确定其表达对病理完全缓解（pCR [ypT0/ypN0]）和生存的影响。有570例患者的样本可用。在48.4%的激素受体阳性肿瘤和58.6%的激素受体阴性肿瘤中观察到低核ER-β表达（免疫反应评分<9）。与高核ER-β表达相比，低核ER-β表达与更高的pCR率相关（16.1%对4.7%，p = 0.026）。在多变量分析中，低ER-β表达不是pCR的独立预测因素。高核和低核ER-β表达患者的无病生存期和总生存期无统计学差异。三阴性乳腺癌中57.7%表现为低核ER-β表达，低ER-β表达和高ER-β表达肿瘤的pCR率分别为27.1%和0%（p = 0.23）。在单变量分析中，低ER-β表达与pCR率提高相关。然而，多变量分析和生存分析并未表明ER-β对接受新辅助化疗患者的生存有影响。进一步研究将ER-β作为内分泌治疗的预测指标可能具有价值。
